search
Back to results

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Primary Purpose

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQB3909 tablet
Sponsored by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Lymphocytic Leukemia

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The subjects volunteered to join the study and signed informed consent form (ICF) with good compliance; Age: ≥ 18 years old, ≤75 years old (when signing ICF); Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; The expected survival period is more than 3 months; Subjects: patients diagnosed as CLL/SLL according to the revised diagnostic criteria of 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines; Computed Tomography / Magnetic Resonance Imaging (CT/MRI) of patients with SLL showed measurable lesions; Female subjects of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7 days before study enrollment; Exclusion Criteria: Complicated diseases and medical history: It has appeared or is currently suffering from other malignant tumors within 3 years before the first medication. The following two situations can be included in the group: other malignant tumors treated by single surgery have achieved disease-free survival (DFS) for five consecutive years; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)]; Lymphoma/leukemia is known to involve the central nervous system (CNS); Previously received allogeneic hematopoietic stem cell transplantation; Received autologous hematopoietic stem cell transplantation within 3 months before the first medication; Unresolved toxic reaction ≥ CTCAE grade 1 caused by any previous treatment; Arterial/venous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage and cerebral infarction), deep venous thrombosis and pulmonary embolism; Subjects with any serious and/or uncontrollable diseases; Tumor-related symptoms and treatment: He has received chemotherapy and radiotherapy within 4 weeks before the first medication, immune checkpoint inhibitor and Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy within 12 weeks before the first medication, and other small molecule anti-tumor treatments (the elution period is calculated from the end of the last treatment) before the first medication are within 5 half-lives; previously received BCL-2 inhibitors; Research-related treatment: received the vaccine within 4 weeks before the first medication, or planned to be vaccinated during the study; Participated in clinical trials of other antineoplastic drugs within 4 weeks before the first medication; According to the investigators' judgment, there are patients with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who think that there are other reasons that are not suitable for inclusion. Allergic to allopurinol and benzbromarone.

Sites / Locations

  • Anqing Municipal HospitalRecruiting
  • Gansu province Wuwei tumour hospitalRecruiting
  • Sun Yat-Sen University Cancer CanterRecruiting
  • Affiliated Hospital of Chengde Medical CollegeRecruiting
  • Harbin first hospitalRecruiting
  • The Second Affiliated Hospital of Harbin Medical UniversityRecruiting
  • Henan Cancer HospitalRecruiting
  • Hunan Cancer HospitalRecruiting
  • Jiangsu Provincial People's HospitalRecruiting
  • The Second Affiliated Hospital of Soochow UniversityRecruiting
  • The First Affiliated Hospital of Soochow UniversityRecruiting
  • Affiliated Hospital of Xuzhou Medical UniversityRecruiting
  • Jiangxi Cancer HospitalRecruiting
  • Shengjing Hospital Affiliated to China Medical UniversityRecruiting
  • Qilu Hospital of Shandong UniversityRecruiting
  • Linyi people's hospitalRecruiting
  • Tai 'an Central HospitalRecruiting
  • Shanghai Tongren HospitalRecruiting
  • Peace Hospital Affiliated to Changzhi Medical CollegeRecruiting
  • Affiliated hospital of southwest medical universityRecruiting
  • Mianyang Central HospitalRecruiting
  • Yibin Second People's HospitalRecruiting
  • Tianjin Cancer HospitalRecruiting
  • The First Affiliated Hospital of Xinjiang Medical UniversityRecruiting
  • The First Affiliated Hospital of Ningbo UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TQB3909 tablets

Arm Description

Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.

Outcomes

Primary Outcome Measures

Incidence of adverse events (AE)
Incidence of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Severity of adverse events (AE)
Severity of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Incidence of serious adverse events (SAE)
Incidence of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Severity of serious adverse events (SAE)
Severity of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Incidence of abnormal laboratory examination indexes.
Incidence of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Severity of abnormal laboratory examination indexes.
Severity of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Recommended phase II dose (RP2D)
To determine the recommended phase II dose of TQB3909 tablets in the treatment of recurrent or refractory CLL/SLL.
Objective remission rate (ORR) determined by Independent Review Committee (IRC)
Determine the objective remission rate (ORR) based on the evaluation results of the Independent Review Committee (IRC), defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).

Secondary Outcome Measures

Objective remission rate (ORR) determined by the investigators' evaluation.
The objective remission rate (ORR) was determined by the results of the investigator s' evaluation, defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).
Duration of remission (DOR)
For all subjects whose best response was PR, CR,, the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).
Time to disease progression (TTP)
Refers to the time from the first medication to the objective progress of the disease.
Time to remission (TTR)
Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population was analyzed.
Progression-free survival (PFS)
The time from the first medication to the objective progression of the disease or death caused from any cause (whichever comes first).
Overall survival (OS)
Time from first dose of study drug to date of death from any cause.
Time to reach maximum concentration (Tmax)
Time to reach maximum plasma concentration after single and multiple dosing of TQB3909 tablets.
Maximum plasma drug concentration (Cmax)
Cmax is the maximum plasma concentration of TQB3909.
Area under the plasma concentration-time curve (AUC0-t)
To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve.
Plasma elimination half-life (t1/2)
t1/2 is time it takes for the blood concentration of TQB3909 to drop by half.
Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow.
Refers to the undetected residual lesions. Peripheral blood and/or bone marrow are used to detect less than 1 CLL cell (less than 10-4) in 10000 white blood cells by flow cytometry.
Correlation between potential biomarkers and TQB3909 tablets.
Correlation of potential biomarkers with TQB3909 tablets: such as BTK and PLCG2 mutation status and allele frequency.

Full Information

First Posted
July 17, 2023
Last Updated
October 19, 2023
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05959694
Brief Title
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Official Title
A Phase Ib/II Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory CLL/SLL.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 11, 2023 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
107 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TQB3909 tablets
Arm Type
Experimental
Arm Description
Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.
Intervention Type
Drug
Intervention Name(s)
TQB3909 tablet
Intervention Description
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
Primary Outcome Measure Information:
Title
Incidence of adverse events (AE)
Description
Incidence of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Severity of adverse events (AE)
Description
Severity of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Incidence of serious adverse events (SAE)
Description
Incidence of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Severity of serious adverse events (SAE)
Description
Severity of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Incidence of abnormal laboratory examination indexes.
Description
Incidence of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Severity of abnormal laboratory examination indexes.
Description
Severity of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time Frame
Up to 34 months.
Title
Recommended phase II dose (RP2D)
Description
To determine the recommended phase II dose of TQB3909 tablets in the treatment of recurrent or refractory CLL/SLL.
Time Frame
Up to 18 months
Title
Objective remission rate (ORR) determined by Independent Review Committee (IRC)
Description
Determine the objective remission rate (ORR) based on the evaluation results of the Independent Review Committee (IRC), defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).
Time Frame
Up to 34 months
Secondary Outcome Measure Information:
Title
Objective remission rate (ORR) determined by the investigators' evaluation.
Description
The objective remission rate (ORR) was determined by the results of the investigator s' evaluation, defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).
Time Frame
Up to 34 months
Title
Duration of remission (DOR)
Description
For all subjects whose best response was PR, CR,, the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).
Time Frame
Up to 34 months
Title
Time to disease progression (TTP)
Description
Refers to the time from the first medication to the objective progress of the disease.
Time Frame
Up to 34 months
Title
Time to remission (TTR)
Description
Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population was analyzed.
Time Frame
Up to 34 months
Title
Progression-free survival (PFS)
Description
The time from the first medication to the objective progression of the disease or death caused from any cause (whichever comes first).
Time Frame
Up to 34 months
Title
Overall survival (OS)
Description
Time from first dose of study drug to date of death from any cause.
Time Frame
Up to 34 months
Title
Time to reach maximum concentration (Tmax)
Description
Time to reach maximum plasma concentration after single and multiple dosing of TQB3909 tablets.
Time Frame
Within 120 hours after administration
Title
Maximum plasma drug concentration (Cmax)
Description
Cmax is the maximum plasma concentration of TQB3909.
Time Frame
Within 120 hours after administration
Title
Area under the plasma concentration-time curve (AUC0-t)
Description
To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve.
Time Frame
Within 120 hours after administration
Title
Plasma elimination half-life (t1/2)
Description
t1/2 is time it takes for the blood concentration of TQB3909 to drop by half.
Time Frame
Within 120 hours after administration
Title
Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow.
Description
Refers to the undetected residual lesions. Peripheral blood and/or bone marrow are used to detect less than 1 CLL cell (less than 10-4) in 10000 white blood cells by flow cytometry.
Time Frame
Up to 34 months
Title
Correlation between potential biomarkers and TQB3909 tablets.
Description
Correlation of potential biomarkers with TQB3909 tablets: such as BTK and PLCG2 mutation status and allele frequency.
Time Frame
Up to 34 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subjects volunteered to join the study and signed informed consent form (ICF) with good compliance; Age: ≥ 18 years old, ≤75 years old (when signing ICF); Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; The expected survival period is more than 3 months; Subjects: patients diagnosed as CLL/SLL according to the revised diagnostic criteria of 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines; Computed Tomography / Magnetic Resonance Imaging (CT/MRI) of patients with SLL showed measurable lesions; Female subjects of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7 days before study enrollment; Exclusion Criteria: Complicated diseases and medical history: It has appeared or is currently suffering from other malignant tumors within 3 years before the first medication. The following two situations can be included in the group: other malignant tumors treated by single surgery have achieved disease-free survival (DFS) for five consecutive years; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)]; Lymphoma/leukemia is known to involve the central nervous system (CNS); Previously received allogeneic hematopoietic stem cell transplantation; Received autologous hematopoietic stem cell transplantation within 3 months before the first medication; Unresolved toxic reaction ≥ CTCAE grade 1 caused by any previous treatment; Arterial/venous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage and cerebral infarction), deep venous thrombosis and pulmonary embolism; Subjects with any serious and/or uncontrollable diseases; Tumor-related symptoms and treatment: He has received chemotherapy and radiotherapy within 4 weeks before the first medication, immune checkpoint inhibitor and Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy within 12 weeks before the first medication, and other small molecule anti-tumor treatments (the elution period is calculated from the end of the last treatment) before the first medication are within 5 half-lives; previously received BCL-2 inhibitors; Research-related treatment: received the vaccine within 4 weeks before the first medication, or planned to be vaccinated during the study; Participated in clinical trials of other antineoplastic drugs within 4 weeks before the first medication; According to the investigators' judgment, there are patients with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who think that there are other reasons that are not suitable for inclusion. Allergic to allopurinol and benzbromarone.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianyong Li, Doctor
Phone
+86 13951877733
Email
Ljianyonglm@mcdmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Keshu Zhou, Doctor
Phone
+86 13674902391
Email
drzhouks77@163.com
Facility Information:
Facility Name
Anqing Municipal Hospital
City
Anqing
State/Province
Anhui
ZIP/Postal Code
246004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fusheng Yao, Doctor
Phone
18955682626
Email
yfsh3792@sina.com
Facility Name
Gansu province Wuwei tumour hospital
City
Wuwei
State/Province
Gansu
ZIP/Postal Code
733000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cong Wang, Bachelor
Phone
13893510690
Email
58589473@qq.com
Facility Name
Sun Yat-Sen University Cancer Canter
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhiming Li, Doctor
Phone
+86 13719189172
Email
lzmlzmlzm@yahoo.com
Facility Name
Affiliated Hospital of Chengde Medical College
City
Chengde
State/Province
Hebei
ZIP/Postal Code
067400
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhihua Zhang, Master
Phone
156333142905
Email
zzhangzhihua@163.com
Facility Name
Harbin first hospital
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tiejun Gong, Master
Phone
13836027737
Email
arc@sina.con
Facility Name
The Second Affiliated Hospital of Harbin Medical University
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wang Wei, Doctor
Phone
13604880743
Email
WW0543@163.com
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keshu Zhou, Doctor
Phone
+86 13674902391
Email
drzhouks77@163.com
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yajun Li, Doctor
Phone
19918803330
Email
158316115@qq.com
Facility Name
Jiangsu Provincial People's Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianyong Li, Doctor
Phone
+8613951877733
Email
Ljianyonglm@mcdmail.com
Facility Name
The Second Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bingzong Li, Doctor
Phone
13776054037
Email
lbzwz0907@hotmail.com
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhengming Jin, Bachelor
Phone
13862553199
Email
jinzhengming519519@163.com
Facility Name
Affiliated Hospital of Xuzhou Medical University
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Feng Zhu, Doctor
Phone
13852439312
Email
Frankfeng_2004@126.com
Facility Name
Jiangxi Cancer Hospital
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wuping Li, Doctor
Phone
13870659916
Email
18907001021@163.com
Facility Name
Shengjing Hospital Affiliated to China Medical University
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Yang, Doctor
Phone
18940251012
Email
yangw@sj-hospital.org
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250063
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Li, Doctor
Phone
18560082232
Email
jieli6688@163.com
Facility Name
Linyi people's hospital
City
Linyi
State/Province
Shandong
ZIP/Postal Code
276002
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haiyan Zhang, Master
Phone
13869986288
Email
13869986288@163.com
Facility Name
Tai 'an Central Hospital
City
Tai'an
State/Province
Shandong
ZIP/Postal Code
271000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingliang Teng, Master
Phone
13375388422
Email
tatql@163.com
Facility Name
Shanghai Tongren Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200050
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ligen Liu, Master
Facility Name
Peace Hospital Affiliated to Changzhi Medical College
City
Changzhi
State/Province
Shanxi
ZIP/Postal Code
460000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xuliang Shen, Doctor
Phone
13015365546
Email
shenxlcyp@sohu.com
Facility Name
Affiliated hospital of southwest medical university
City
Luzhou
State/Province
Sichuan
ZIP/Postal Code
646000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaoming Li, Master
Phone
13700986866
Email
LXM6358@21.com.cn
Facility Name
Mianyang Central Hospital
City
Mianyang
State/Province
Sichuan
ZIP/Postal Code
621000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaobo Du, Doctor
Phone
13550822229
Email
Duxiaobo2005@126.com
Facility Name
Yibin Second People's Hospital
City
Yibin
State/Province
Sichuan
ZIP/Postal Code
644000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sihua Huang, Bachelor
Phone
18284820022
Facility Name
Tianjin Cancer Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yafei Wang, Doctor
Phone
18622221250
Email
Drwang2005@163.com
Facility Name
The First Affiliated Hospital of Xinjiang Medical University
City
Ürümqi
State/Province
Xinjiang Uygur Autonomous Region
ZIP/Postal Code
830054
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianhua Qu, Master
Phone
13199855506
Email
jhuaqu@163.com
Facility Name
The First Affiliated Hospital of Ningbo University
City
Ningbo
State/Province
Zhejiang
ZIP/Postal Code
315010
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guifang Ouyang, Master
Phone
13967810405
Email
nbougf@163.com

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

We'll reach out to this number within 24 hrs